Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

[1]  U. Reuter,et al.  Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study , 2021, Cephalalgia : an international journal of headache.

[2]  M. Filippi,et al.  Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study , 2021, Headache.

[3]  J. Olesen,et al.  Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency , 2021, Headache.

[4]  D. Viceic,et al.  Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study , 2021, Cephalalgia : an international journal of headache.

[5]  C. Lovati,et al.  Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) , 2021, The Journal of Headache and Pain.

[6]  Y. Cao,et al.  Increase in trigeminal ganglion neurons that respond to both calcitonin gene–related peptide and pituitary adenylate cyclase–activating polypeptide in mouse models of chronic migraine and posttraumatic headache , 2021, Pain.

[7]  M. Filippi,et al.  Pathophysiological Bases of Comorbidity in Migraine , 2021, Frontiers in Human Neuroscience.

[8]  Chun-Pai Yang,et al.  Prevalence and association of lifestyle and medical‐, psychiatric‐, and pain‐related comorbidities in patients with migraine: A cross‐sectional study , 2021, Headache.

[9]  E. Pearlman,et al.  Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials , 2021, Advances in Therapy.

[10]  S. Silberstein,et al.  Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial , 2021, European journal of neurology.

[11]  S. Sacco,et al.  Early outcomes of migraine after erenumab discontinuation: data from a real-life setting , 2021, Neurological Sciences.

[12]  P. Calabresi,et al.  A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB , 2020, The Journal of Headache and Pain.

[13]  A. Andreou,et al.  A prospective real-world analysis of erenumab in refractory chronic migraine , 2020, The Journal of Headache and Pain.

[14]  Carrie R. Houts,et al.  Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review , 2019, Headache.

[15]  S. Silberstein,et al.  Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) , 2019, The Journal of Headache and Pain.

[16]  U. Reuter,et al.  Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination , 2019, The Journal of Headache and Pain.

[17]  W. Kielbasa,et al.  A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody , 2019, Cephalalgia : an international journal of headache.

[18]  S. Sacco,et al.  European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention , 2019, The Journal of Headache and Pain.

[19]  R. Conley,et al.  Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial , 2018, JAMA neurology.

[20]  L. Edvinsson,et al.  CGRP as the target of new migraine therapies — successful translation from bench to clinic , 2018, Nature Reviews Neurology.

[21]  S. Silberstein,et al.  Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial , 2018, JAMA.

[22]  D. Grayzel,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers , 2017, Front. Pharmacol..

[23]  M. Arnold.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.